Everolimus (RAD001) combined with programmed death-1 (PD-1) blockade enhances radiosensitivity of cervical cancer and programmed death-ligand 1 (PD-L1) expression by blocking the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR)/S6 kinase 1 (S6K1) pathway

Lili Songa Department of Obstetrics and Gynecology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, ChinaView further author information

Shikai Liub Department of Obstetrics and Gynecology, Cangzhou Central Hospital, Cangzhou, Hebei, ChinaView further author information

Sufen Zhaoa Department of Obstetrics and Gynecology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, ChinaCorrespondence[email protected]
View further author information

Citations (2)

Keep up to date with the latest research on this topic with citation updates for this article.